Miller W T
Am Rev Respir Dis. 1978 Mar;117(3):605-7. doi: 10.1164/arrd.1978.117.3.605.
The secondary antibody response was studied in 22 patients with tuberculosis, 11 of whom were taking rifampin as part of their antituberculous regimen. The mean duration of rifampin therapy was 12.7 months. Hemagglutination-inhibiting antibody titers to bivalent influenza vaccine were determined before, and 4 and 8 weeks after, vaccination. There was no significant difference in the number of patients who developed a 4-fold or greater increase in titer, or in the level of titer response between the rifampin and control groups. Long-term therapy with rifampin was not found to suppress the secondary antibody response to influenza vaccination.
对22例结核病患者的二次抗体反应进行了研究，其中11例患者将利福平作为抗结核治疗方案的一部分。利福平治疗的平均时长为12.7个月。在接种二价流感疫苗前、接种后4周和8周，测定了血凝抑制抗体滴度。在滴度升高4倍或更高的患者数量，或利福平组和对照组之间的滴度反应水平方面，未发现显著差异。未发现利福平长期治疗会抑制对流感疫苗接种的二次抗体反应。
